Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26468810 | 0.96 | AHR (0.31) | AHRPGRECE1L3MBTL1KDM4E | |
| SCHEMBL26468802 | 0.93 | PGR (0.34) | PGRECE1BACE1L3MBTL1KDM4E | |
| SCHEMBL26468794 | 0.90 | PGR (0.36) | PGRECE1BACE1L3MBTL1KDM4E | |
| SCHEMBL26468806 | 0.88 | PGR (0.34) | PGRECE1L3MBTL1KDM4EHPGD | |
| SCHEMBL26468813 | 0.87 | CCR1 (0.33) | BACE1L3MBTL1KDM4ETSHRRAB9A | |
| SCHEMBL26468516 | 0.86 | ALOX5 (0.33) | AHRBACE1L3MBTL1KDM4EHPGD | |
| SCHEMBL26468737 | 0.83 | PGR (0.35) | PGRECE1L3MBTL1KDM4EHPGD | |
| SCHEMBL26468793 | 0.82 | ALOX5 (0.36) | ECE1BACE1L3MBTL1KDM4EHPGD | |
| SCHEMBL26468828 | 0.82 | BACE1 (0.34) | BACE1L3MBTL1KDM4ETSHRRAB9A | |
| SCHEMBL26468809 | 0.82 | CCR1 (0.33) | BACE1L3MBTL1KDM4ETSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | PPOX, PAH, CRY2 | AHR 5/4885PGR 2588/4885ECE1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.